Trial Profile
A Pilot Study of Imatinib Mesylate in Children and Adults With Sclerotic Skin Changes of Chronic Graft-Versus-Host Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 01 Aug 2020 Results (n=13) of secondary analysis published in the Supportive Care in Cancer
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 May 2012 Planned end date changed from 1 Mar 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.